News
VIRI
0.2360
+1.81%
0.0042
Optimistic Buy Rating for Virios Therapeutics as IMC-2 Advances in Clinical Trials with Promising Phase 2 Results
TipRanks · 2d ago
VIRIOS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN IMC-2 PHASE 2 LONG-COVID STUDY BEING CONDUCTED BY BATEMAN HORNE CENTER
Reuters · 3d ago
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s mid-day session. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. MIRA Pharmaceuticals,. Inc. Shares climbed 148% to $1.98. Selective Insurance Group shares dipped 13.2%.
Benzinga · 4d ago
Weekly Report: what happened at VIRI last week (0715-0719)?
Weekly Report · 4d ago
Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
Shares of Tellurian Inc. Rose sharply in today's pre-market trading. Woodside Energy announced plans to acquire the company for $900 million in all-cash deal. Netcapital Inc. Shares rose 43.8% to $0.1495 after jumping more than 12% on Friday.
Benzinga · 4d ago
Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
Shares of Chuy’s Holdings, Inc. Rose sharply in today's pre-market trading. The company and Darden Restaurants announced that Darden will acquire Chuy's Holdings. Onconetix, Inc.'s shares rose 65% on Wednesday. Leslie's, Inc., and Stardust Power Inc. Were among the losers in pre- market trading.
Benzinga · 07/18 10:00
Weekly Report: what happened at VIRI last week (0708-0712)?
Weekly Report · 07/15 11:41
Weekly Report: what happened at VIRI last week (0701-0705)?
Weekly Report · 07/08 11:43
Weekly Report: what happened at VIRI last week (0624-0628)?
Weekly Report · 07/01 11:43
Weekly Report: what happened at VIRI last week (0617-0621)?
Weekly Report · 06/24 11:52
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading. The company disclosed a strategic partnership with Avegant to develop optimized waveguide optical modules for use in future AI-enabled smart glasses. SMX (Security Matters) shares jumped 109.8% on Tuesday.
Benzinga · 06/20 12:22
Virios Therapeutics Price Target Announced at $1.00/Share by Maxim Group
Dow Jones · 06/20 11:58
Virios Therapeutics Initiated at Buy by Maxim Group
Dow Jones · 06/20 11:58
Maxim Group Initiates Coverage On Virios Therapeutics with Buy Rating, Announces Price Target of $1
Benzinga · 06/20 11:47
VIRIOS THERAPEUTICS INC <VIRI.O>: MAXIM GROUP INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $1
Reuters · 06/20 11:35
U.S. RESEARCH ROUNDUP-Citigroup, Nike, Tesla
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. Citigroup, Nike, Tesla and Lennar among companies with revised targets. Lennar Corp cuts target price to $177 from $180. Bread Financial Holdings Inc, Ball Corp and Allstate also see price targets cut.
Reuters · 06/20 07:03
Weekly Report: what happened at VIRI last week (0610-0614)?
Weekly Report · 06/17 11:42
Weekly Report: what happened at VIRI last week (0603-0607)?
Weekly Report · 06/10 11:44
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
G-III Apparel Group shares dipped 13.4% to $27.12 on Thursday. The company reported worse-than-expected quarterly sales results. Virax Biolabs Group Limited and American Oncology Network were among the stocks moving in the mid-day session.
Benzinga · 06/06 17:39
Weekly Report: what happened at VIRI last week (0527-0531)?
Weekly Report · 06/03 11:48
More
Webull provides a variety of real-time VIRI stock news. You can receive the latest news about Virios Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VIRI
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.